Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL) will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online from November 11-14. The company will present its ImmunoID NeXT™ platform, which enables comprehensive analysis of tumors and their immune microenvironment from a single sample. Key poster presentations include topics like tumor circulating cell-free DNA profiling and precision neoantigen discovery. Additionally, an industry symposium on maximizing immunotherapy biomarker discovery will take place on November 12.

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online, November 11-14, including poster presentations on November 11^th – 13^th.

The company will showcase ImmunoID NeXT™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

Following is a list of abstracts that will be presented at the meeting.

Scientific Poster Presentations

Poster Number & Category		Title & Presenter		Day & Time
29 Biomarkers, Immune Monitoring, and Novel Technologies		Profiling Tumor Circulating Cell-Free DNA with an Enhanced Whole-Exome to Enable Sensitive Assessment of Somatic Mutations Presenter: Simo V. Zhang, PhD		NOV 11 | 5:15 – 5:45 PM EST and NOV 13 | 4:40 – 5:10 PM EST
57 Biomarkers, Immune Monitoring, and Novel Technologies		Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets Presenter: Dattatreya Mellacheruvu, PhD		NOV 11 | 5:15 – 5:45 PM EST and NOV 13 | 4:40 – 5:10 PM EST
67 Biomarkers, Immune Monitoring, and Novel Technologies		B-cell receptor heavy chain repertoire profiling using an augmented transcriptome Presenter: Eric Levy, Ph.D.		NOV 11 | 5:15 – 5:45 PM EST and NOV 13 | 4:40 – 5:10 PM EST
73 Biomarkers, Immune Monitoring, and Novel Technologies		Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity Presenter: Rachel M. Pyke, PhD		NOV 11 | 5:15 – 5:45 PM EST and NOV 13 | 4:40 – 5:10 PM EST

Following are details of an industry-sponsored symposium which will be presented at the meeting.

Industry Sponsor Symposium

Presentation Category		Title & Presenter		Day & Time
Sponsored Symposia		Maximizing immunotherapy biomarker discovery with a multidimensional tumor immunogenomics platform Presenter: Erin N. Newburn, PhD		NOV 12 | 12:30 – 12:50 PM EST

Personalis will also be exhibiting during the online conference. Representatives will be available to answer questions about the company’s cancer immunogenomics services.

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis^® ImmunoID NeXT Platform^® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).